Friday 6 November 2026
Export LH’s income statement to Excel — free account
Labcorp Holdings Inc.
LH Healthcare Diagnostics & Research
Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024.
- Revenue
- +6.92%
- EPS
- +3.18%
- Free cash flow
- +44.7%
- Total debt
- +3.21%
Quarter to September 2026, against a year earlier
362.28
5.51
−1.50%
Follow LH
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
25.11 | 23.01 | 23.49 | 23.80 |
+8 more quarters Free account |
P/S ratio |
1.71 | 1.59 | 1.55 | 1.50 | |
P/FCF ratio |
21.60 | 22.16 | 17.41 | 19.40 | |
P/Operating CF |
44.32 | 51.35 | 114.67 | 33.98 | |
P/B ratio |
2.82 | 2.66 | 2.52 | 2.42 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.06 | 2.00 | 1.90 | 1.83 | |
EV/EBITDA |
13.61 | 13.07 | 12.63 | 12.34 | |
EV/Operating CF |
16.55 | 17.49 | 14.82 | 15.54 | |
EV/FCF |
25.97 | 27.76 | 21.31 | 23.69 | |
Quick Ratio |
1.00 | 1.25 | 1.30 | 0.99 | |
Current Ratio |
1.41 | 1.80 | 1.73 | 1.42 | |
Net Debt/EBITDA |
6.92 | 9.16 | 8.87 | 15.83 | |
Debt/Assets |
28.07% | 31.94% | 30.89% | 27.99% | |
Debt/Equity |
0.60 | 0.69 | 0.68 | 0.60 | |
Asset Turnover |
0.78 | 0.78 | 0.77 | 0.76 | |
Operating CF/Net income |
2.15 | 1.49 | 0.69 | 3.73 | |
Capex/Depreciation |
(0.49) | (0.72) | (0.65) | (4.85) | |
Interest Coverage |
6.80 | 7.39 | 6.91 | 4.87 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.05% | 15.47% | 15.58% | 15.30% | |
Intangible Assets out of Total Assets |
0.58 | 0.58 | 0.55 | 0.56 | |
Share Based Compensation of Revenue |
0.81% | 0.94% | 0.90% | 0.84% | |
Graham Net Nets |
(0.24) | (0.27) | (0.26) | (0.28) | |
Graham Number |
173.55 | 169.84 | 164.65 | 156.75 | |
Earnings Yield |
3.98% | 4.35% | 4.26% | 4.20% | |
Free Cash Flow Yield |
4.63% | 4.51% | 5.74% | 5.15% | |
Revenue per Share |
46.98 | 45.67 | 42.98 | 42.26 | |
Operating CF per Share |
6.95 | 5.45 | 2.33 | 7.38 | |
Capex per Share |
(1.99) | (1.59) | (1.38) | (1.39) | |
Free Cash Flow per Share |
4.96 | 3.87 | 0.95 | 5.99 | |
Cash per Share |
3.23 | 1.74 | 11.92 | 6.40 | |
Shareholders Equity per Share |
109.10 | 105.35 | 106.06 | 103.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
109.10 | 105.35 | 106.06 | 103.60 | |
Free Cash Flow |
402.50 | 315.80 | 78.30 | 498.30 | |
Working Capital |
1,146.60 | 1,690.30 | 1,917.80 | 1,197.00 | |
Capital Expenditures |
(161.30) | (129.70) | (113.20) | (115.90) | |
Net Current Asset Value |
(6,110.60) | (6,110.60) | (5,799.70) | (5,752.40) | |
EV/EBIT |
20.00 | 19.15 | 18.67 | 18.41 | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.03 | |
Price to Operating Income |
16.64 | 15.29 | 15.25 | 15.07 | |
| Other line items | |||||
Average Receivables |
2,411.95 | 2,390.75 | 2,362.50 | 2,178.85 | |
Average Payables |
703.25 | 740.75 | 706.80 | 858.30 | |
Average Inventory |
529.95 | 535.15 | 493.00 | 513.95 | |
Average Assets |
18,593.10 | 18,296.10 | 18,345.45 | 18,385.85 | |
Average Common Equity |
8,772.35 | 8,539.75 | 8,518.00 | 8,336.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026